ABSTRACT
There currently exists no formal consensus on advice given to patients who have experienced an adverse event following immunization (AEFI) (WHO definition) following COVID-19 vaccination. The incidence of vaccine-related cutaneous events is only likely to increase with the UK launching subsequent vaccine doses as part of the mass vaccination programme due to concerns about waning immunity. We present a small multicentre case series of 13 patients presenting with cutaneous-only AEFI from February to August 2021. Patients were between the ages of 21 and 83 years, from multiple ethnicities across secondary and tertiary care trusts in the UK and Hong Kong. The case series demonstrated a phenotypic spectrum of cutaneous manifestations not previously categorized in current literature. Along with our literature review, we have been able to surmise that cutaneous AEFI remain exceptionally rare and this should not be used as cautionary evidence against vaccination. On the contrary, better understanding of AEFI would serve to aid clinicians and patients on making informed decisions based on risk- benefit analysis. It is our aim that this pragmatic approach, taking into account multiple variable factors, would serve to aid in recommendations on vaccination as new evidence emerges over time.